# A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms

> **NCT03603951** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 272 (actual)

## Conditions studied

- Relapsed or Refractory Mature Lymphoid Neoplasms

## Interventions

- **DRUG:** SHR2554

## Key facts

- **NCT ID:** NCT03603951
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-08-14
- **Primary completion:** 2026-02-14
- **Final completion:** 2026-08-14
- **Target enrollment:** 272 (ACTUAL)
- **Last updated:** 2024-10-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03603951

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03603951, "A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03603951. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*